Back to School: How biopharma can reboot drug development. Access exclusive analysis here

July 23 Quick Takes: Priority Review for Aurinia; plus Jazz, CymaBay, Biogen, Vertex, Grünenthal, Mesoblast, BMS and Genfit

Priority Review for Aurinia’s lupus nephritis therapy
FDA accepted and granted Priority Review to an NDA for voclosporin from Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH; TSX:AUP) to treat lupus nephritis. The PDUFA date for the immune-suppressing, IL-2-blocking calcineurin inhibitor is in January.

FDA approves Jazz’s narcolepsy therapy
FDA approved Xywav from Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to treat

Read the full 521 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE